医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sengenics, a Leading Precision Medicine Focused Company, to Present at the Annual BIO CEO and Investor Conference

2020年01月28日 PM11:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Sengenics, a leading precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, will present a company overview at the 2020 BIO CEO and Investor Conference. The presentation will take place at 3:15 PM EST on Monday, February 10, 2020 in the Wilder room at the New York Marriott Marquis.

Dr Arif Anwar will present an overview of the commercialisation strategy of the company and applications of its patented KREXTM technology for autoimmune and cancer immunotherapy drug response and ADR prediction.

Sengenics is currently co-developing complementary and companion diagnostic tests for several autoimmune and cancer immunotherapy drugs through partnerships with top pharmaceutical companies. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020 and 2021.

Sengenics’ management team will also hold meetings with institutional investors and analysts from February 10 – 14 in New York. Accredited investors are invited to request a meeting during the conference through BIO’s One-on-One PartneringTM System.

About Sengenics

Sengenics is a precision medicine company that leverages its patented KREXTM technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREXTM can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005345/en/

CONTACT

Media

Farah Elena

Marketing Manager

Sengenics Corporation Pte Ltd

f.elena@sengenics.com

Business Development and Partnerships

Andrew James Jackson

Global Business Unit Director – Pharma

Sengenics Corporation Pte Ltd

a.jackson@sengenics.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Coronavirus IS a Pandemic — WHO, Declare It Now!
  • Hot Topics Recap: Coronavirus
  • Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
  • Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
  • CGTN: How China Mobilizes Whole Country to Contain Coronavirus Disease 2019 (COVID-19)